NCT03245177View on ClinicalTrials.gov

Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

August 31, 2017

Primary Completion Date

August 1, 2019

Study Completion Date

August 1, 2019

Conditions

Non Small Cell Lung Cancer

Interventions

BIOLOGICAL

Pembrolizumab

Anti-PD-1 antibody

RADIATION

Radiotherapy

60-66 Gy in 30-33 fractions, 2 Gy per fraction

Sponsors

Collaborators (1)

Cancer Research UK

All Listed Sponsors

collaborator

University of Leeds

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Cancer Research UK

OTHER

lead

Prof Corinne Faivre-Finn

OTHER